Results from two studies suggest that withholding chemotherapy for some patients may not impact efficacy, but an understanding of clinical and biological features is paramount
Recent studies have refined current knowledge on how to better treat this patient population, taking care of their unique needs and expectations
Retrospective data suggest that patients with low baseline TILs and nodal involvement have poor prognosis despite achieving pathological complete response
Final long-term overall survival data from APHINITY confirm the efficacy of dual HER2 blockade in patients with node-positive disease
A timing window for testing ESR1 mutations in the blood was identified
Defining patients most likely to respond, a better understanding of the host–tumour immune axis and clinical trials for specific subtypes are key to extending success
The 2025 ESMO Breast Cancer Awardee highlights that participation in clinical trials and the contribution of patient advocates is as relevant as technology to progress…
While AI tools have shown promise in reducing false positives and aiding radiologists, large prospective trials are now exploring how technology should be integrated in…
#ESMOBreast25: Do not miss the latest research findings in #BreastCancer brought to you by the #ESMO
Follow #ESMOBreast25 on Facebook, X (Twitter), LinkedIn, Instagram and YouTube.
